logo-loader
viewLandos Biopharma

Landos Biopharma kicks off Phase 1 clinical study for its treatment of IBD

Landos Biopharma CEO Josep-Bassaganya-Riera tells Proactive Investors the biopharma has very high expectations on how the company's drug, BT-11, will move forward.

Landos began dosing the drug in Phase 1 clinical study in July, they anticipate results in November.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Perseus Mining reports 'minimal impact' from coronavirus but is well placed...

Perseus Mining Limited's (ASX:PRU) Jeff Quartermaine talks Proactive's Andrew Scott through their planning for COVID-19 and how they're 'well-positioned' to deal with the outbreak.  He says they're adapting its activities around the current pandemic using systems developed during the...

1 day, 12 hours ago

2 min read